|
Age at transplantation in years
|
Median: 12.7 (0.4–65.4); mean: 22.3
|
|
Time to diagnosis after transplantation in years
|
Median: 2.1 (0.3–19); mean: 3.8
|
|
Age at PTLD diagnosis in years
|
Median: 15.7 (0.8–70.8); mean: 26.1
|
|
Age > 60 years at PTLD diagnosis
|
n = 4 (11.1 %)
|
|
Age < 10 years at PTLD diagnosis
|
n = 14 (38.9 %)
|
|
Age < 5 years at PTLD diagnosis
|
n = 11 (30.6 %)
|
|
Late PTLD (>365 days after Tx)
|
n = 24 (66.7 %)
|
|
Very early PLTD (<183 days after Tx)
|
n = 4 (11.1 %)
|
|
Ciclosporine at PTLD diagnosis
|
n = 15 (41.7 %)
|
|
Tacrolimus at PTLD diagnosis
|
n = 16 (44.4 %)
|
|
CNI-free immunosuppression at PTLD diagnosis
|
n = 5 (13.9 %)
|
|
Mycophenolat at PTLD diagnosis
|
n = 19 (52.8 %)
|
|
Steroids at PTLD diagnosis
|
n = 29 (80.6 %)
|
|
Steroid-free immunosuppression at PTLD diagnosis
|
n = 7 (19.4 %)
|
|
mTOR inhibitors at PTLD diagnosis
|
n = 1 (2.8 %)
|
|
Number of graft rejections prior to PTLD diagnosis
|
Median: 0 (0–2); mean: 0.44
|
|
Number of graft rejections after PTLD diagnosis
|
Median: 0 (0–1); mean: 0.25
|
|
Polymorphic PTLD
|
n = 5 (13.9 %)
|
|
Monomorphic PTLD
|
n = 28 (77.8 %)
|
|
Pure B cell neoplasm
|
n = 29 (80.6 %)
|
|
Diffuse large B cell neoplasm
|
n = 20 (55.6 %)
|
|
CD20 expression in tumor
|
n = 32 (88.9 %)
|
|
EBV latent membrane protein or EBV-encoded RNA in tumor cells
|
n = 26 (100.0 %a, 10 cases missing data)
|
|
Detection of monoclonal disease
|
n = 9 (52.9 %a, 19 cases missing data)
|
|
Extranodal disease
|
n = 24 (66.7 %)
|
|
Graft organ involvement
|
n = 4 (11.1 %)
|
|
CNS involvement
|
n = 7 (19.4 %)
|
|
Primary CNS lymphoma
|
n = 4 (11.1 %)
|
|
Bone marrow involvement
|
n = 6 (16.7 %)
|
|
Gastro-intestinal involvement
|
n = 14 (38.9 %)
|
|
Lung involvement
|
n = 3 (8.3 %)
|
|
Skin involvement
|
n = 0 (0.0 %)
|
|
Number of sites involved
|
Median: 2 (1–6); mean: 2.5
|
|
Stage IV disease
|
n = 25 (69.4 %)
|
|
B-symptoms at PTLD diagnosis
|
n = 4 (11.1 %)
|
|
Lactate dehydrogenase elevated at PTLD diagnosis
|
n = 23 (71.9 %a, 4 cases missing data)
|
|
Hypoalbuminemia at PTLD diagnosis
|
n = 17 (65.4 %a, 10 cases missing data)
|
|
EBV IgG at Tx
|
n = 14 (45.2 %a, 5 cases missing data)
|
|
EBV IgM at Tx
|
n = 1 (3.3 %a, 6 cases missing data)
|
|
EBV serology or DNA positive at PTLD diagnosis
|
n = 31 (100.0 %a, 5 cases missing data)
|
|
EBV DNA at PTLD diagnosis
|
n = 29 (96.7 %a, 6 cases missing data)
|
|
EBV IgG at PTLD diagnosis
|
n = 21 (77.8 %a, 9 cases missing data)
|
|
CMV IgG at Tx
|
n = 12 (35.3 %a, 2 cases missing data)
|
|
CMV IgM at Tx
|
n = 3 (9.7 %a, 5 cases missing data)
|
|
CMV pp65 at Tx
|
n = 1 (3.8 %a, 10 cases missing data)
|
|
CMV serology or DNA positive at PTLD diagnosis
|
n = 23 (100 %a, 13 cases missing data)
|
|
CMV pp65 at PTLD diagnosis
|
n = 1 (4.2 %a, 12 cases missing data)
|
|
CMV DNA at PTLD diagnosis
|
n = 4 (22.2 %a, 18 cases missing data)
|
|
CMV IgM at PTLD diagnosis
|
n = 7 (30.4 %a, 13 cases missing data)
|
|
CMV IgG at PTLD diagnosis
|
n = 21 (77.8 %a, 9 cases missing data)
|
